Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

Abstract Background Biliary tract cancer (BTC) has a poor prognosis and lacks a standardized second-line therapy. Vascular endothelial growth factor (VEGF), fibroblast growth factor receptor (FGFR) 4, and platelet-derived growth factor receptor (PDGFR) are highly expressed in BTC. Therefore, lenvati...

Full description

Bibliographic Details
Main Authors: Makoto Ueno, Masafumi Ikeda, Takashi Sasaki, Fumio Nagashima, Nobumasa Mizuno, Satoshi Shimizu, Hiroki Ikezawa, Nozomi Hayata, Ryo Nakajima, Chigusa Morizane
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Cancer
Subjects:
Lenvatinib
Biliary tract cancer
Cholangiocarcinoma
Gallbladder cancer
Ampulla of Vater
Online Access:http://link.springer.com/article/10.1186/s12885-020-07365-4

Internet

http://link.springer.com/article/10.1186/s12885-020-07365-4

Similar Items